medgenetx.com | Immunotherapy | Medgene Therapeutics,

Robots.txt Information

Robot	Path	Permission
GoogleBot	/	✔
BingBot	/	✔
BaiduSpider	/	✔
YandexBot	/	✔
User-agent: * Allow: / # Optimization for Google Ads Bot User-agent: AdsBot-Google-Mobile User-agent: AdsBot-Google Disallow: /_api/* Disallow: /_partials* Disallow: /pro-gallery-webapp/v1/galleries/* # Block PetalBot User-agent: PetalBot Disallow: / Sitemap: https://www.medgenetx.com/sitemap.xml # Auto generated, go to SEO Tools > Robots.txt Editor to change

Meta Tags

Title	Immunotherapy \| Medgene Therapeutics,
Description	MedGene Therapeutics, Inc. Autologous Adoptive Cell Therapy and Anti T Cell
Keywords	Simplify, Your

Server Information

WebSite	medgenetx.com
Host IP	23.236.62.147
Location	United States

Related Websites

                        Site
                        Rank
                    

More to Explore

medgenetx.com Valuation

US$1,470

Last updated: 2023-05-20 07:15:23

medgenetx.com has Semrush global rank of 0. medgenetx.com has an estimated worth of US$ 1,470, based on its estimated Ads revenue. medgenetx.com receives approximately 169 unique visitors each day. Its web server is located in United States, with IP address 23.236.62.147. According to SiteAdvisor, medgenetx.com is safe to visit.

Traffic & Worth Estimates

Purchase/Sale Value	US$1,470
Daily Ads Revenue	US$1
Monthly Ads Revenue	US$40
Yearly Ads Revenue	US$488
Daily Unique Visitors	11
Note: All traffic and earnings values are estimates.

DNS Records

Host	Type	TTL	Data
medgenetx.com.	A	3599	IP: 23.236.62.147
medgenetx.com.	NS	86400	NS Record: ns7.wixdns.net.
medgenetx.com.	NS	86400	NS Record: ns6.wixdns.net.
medgenetx.com.	MX	3600	MX Record: 10 aspmx3.googlemail.com.
medgenetx.com.	MX	3600	MX Record: 5 alt2.aspmx.l.google.com.
medgenetx.com.	MX	3600	MX Record: 5 alt1.aspmx.l.google.com.
medgenetx.com.	MX	3600	MX Record: 10 aspmx2.googlemail.com.
medgenetx.com.	MX	3600	MX Record: 1 aspmx.l.google.com.

HtmlToTextCheckTime:2023-05-20 07:15:23

top of page MEDGENE THERAPEUTICS, INC. About About MedGene Vision and Strategy Technologies About PBL-T The PBL-T Advantage About RIV-8 The RIV-8 Advantage About AUTO-T Pipelines Pipelines Pipelines Graphic Team News News Investors Principles Contact MEDGENE THERAPEUTICS, INC. PBL-T™ Therapy and RIV-8: Redefining Cancer Therapies Home: About Us MedGene Therapeutics is: MedGene Therapeutics is developing twin foundational technologies for cell therapy targeting solid tumors. PBL-T™ is a version of Tumor Infiltrating Lymphocyte (TIL) therapy based on obtaining anti-cancer T cells from blood rather than tumor tissue. Developed by Dr. Steven A. Rosenberg, this technology was patented by NIH and is exclusively licensed to MedGene. RIV-8™ is an anti-T cell exhaustion protocol which both prevents and reverses the problem of the persistent fading of T cell anti-tumor activity in patients, Developed by Dr. Rho H. Seong, MedGene’s Chief Science Advisor, RIV-8™ is owned exclusively by

HTTP Headers

HTTP/1.1 301 Moved Permanently
Date: Sat, 21 Jan 2023 09:07:51 GMT
Content-Length: 0
Connection: keep-alive
location: https://www.medgenetx.com/
strict-transport-security: max-age=3600
Age: 43916
Server-Timing: cache;desc=hit, varnish;desc=hit, dc;desc=uw2-pub-1
X-Seen-By: Qizr2MOzfO8jjTBKBVmOj6nPWIDxfKj16yM6xXYJ3IE=,GXNXSWFXisshliUcwO20Naon851uhK6HRsxREnrEO9Y+DYuMfmtB4kgQ8tW/ClTAmuOkfcTSJaUOHlD2KQbqrA==,m0j2EEknGIVUW/liY8BLLuxuneWIxsREdYD1q4BIALwG/hKs8AeY1T4OIbgnD+yx,2d58ifebGbosy5xc+FRalt8ScUzxcjbknRZexJW15661/SPebQieS1xO77DAY4hwdNcUqQyZ/GQXrjBTmT42ng==,2UNV7KOq4oGjA5+PKsX47O6uVG6buAunlWjI2L90d5VjPZTuGyYqVhtmEIgJUb4w
Cache-Control: no-cache
X-Wix-Request-Id: 1674292071.80714319334016288
X-Content-Type-Options: nosniff

HTTP/2 200 
date: Sat, 21 Jan 2023 09:07:52 GMT
content-type: text/html; charset=UTF-8
link: ; rel=preconnect; crossorigin;,; rel=preconnect;,; rel=preconnect; crossorigin;,; rel=preconnect;,; rel=preconnect; crossorigin;,
x-wix-request-id: 1674292071.9995303348528482
content-language: en
strict-transport-security: max-age=3600
age: 0
x-seen-by: GXNXSWFXisshliUcwO20NZL9Lwun+M+7c/tw2Pto8/HpB1e4fStpawOReABU4/eI,qquldgcFrj2n046g4RNSVLeuNqwcdH46iMA2Je1RdMI=,2d58ifebGbosy5xc+FRaloI9RED2V3FURsb3YlXVPPhtPnqwqoXFtT13uQ9NQo7sjoe2GMQJ/MdiMK4Y/vI70wIIkTOZGLBJPIvcX184Sn8=,2UNV7KOq4oGjA5+PKsX47AvrMO/f+Z3GvorMN0miK2BYgeUJqUXtid+86vZww+nL,7npGRUZHWOtWoP0Si3wDp3pk+fOCkUHYAkRreQULO2E=,m86p0LbwQP79i4nFFg3YptTPWCWWbhUm/owVc+xlKnRSWiTSpqtJno+cWPcTXGusrnLUM0uZR+feBD0CloR/5g==,xTu8fpDe3EKPsMR1jrheEA0OBLja1mZCnsT7Z/KiaN0=,LoUK8/saGAmOxZWtpubo2leTAIKm/bEWaMRniwm9S9yNRec7lJhvaKj7Qr6YrsVCGgbHGJjjDn6hE5ugS+NF2g==,xTu8fpDe3EKPsMR1jrheEGumlZLSMfM8xhXijje3r20=,xTu8fpDe3EKPsMR1jrheEEA/WK9PEnFFyLYbXSAgqks=,/a5ccLSK1HEmwPNg/x6OuhwVf+M/llv4ecAdPJ9TQifDzCequWMto2p805NS5MC102xjxirrVVGvMTgLa9a9jg==
cache-control: no-cache
vary: Accept-Encoding
accept-ranges: bytes
set-cookie: ssr-caching=cache#desc=miss#varnish=miss#dc#desc=euw3_g; Max-Age=20; Expires=Sat, 21 Jan 2023 09:08:12 GMT
server-timing: cache;desc=miss, varnish;desc=miss, dc;desc=euw3_g
x-content-type-options: nosniff
server: Pepyaka/1.19.10
via: 1.1 google
alt-svc: h3=":443"; ma=2592000,h3-29=":443"; ma=2592000,h3-Q050=":443"; ma=2592000,h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000,quic=":443"; ma=2592000; v="46,43"

medgenetx.com valuation and analysis